Impaired insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients

Pancreas

Volumn 26, Issue 2, 2003, Pages 173-177

  Isaksson, Bengt ^a,d   Strömmer, Lisa ^a   Friess, Helmut ^b   Büchler, Markus W ^b   Herrington, Margery K ^a,c   Wang, Feng ^a   Zierath, Juleen R ^a   Wallberg Henriksson, Harriet ^a   Larsson, Jörgen ^a   Permert, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF BERN   (Switzerland)

^c ADAMS STATE COLLEGE   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Glucose transport; Glucose transporter 4 (GLUT4); Insulin resistance; Pancreatic cancer; PI 3 kinase; Skeletal muscle

Indexed keywords

GLUCOSE TRANSPORTER 4; INSULIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ABDOMINAL WALL MUSCULATURE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; HORMONE ACTION; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; MALE; PANCREAS CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION; SKELETAL MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; 3-O-METHYLGLUCOSE; AGED; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORTER TYPE 4; HUMANS; INSULIN; MALE; MIDDLE AGED; MONOSACCHARIDE TRANSPORT PROTEINS; MUSCLE PROTEINS; MUSCLE, SKELETAL; PANCREATIC NEOPLASMS;

EID: 20244370689     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200303000-00014     Document Type: Article

References (28)

1. Schwarts SS, Zeidler A, Moossa AR, et al. A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. Am J Dig Dis 1978;23:1107-14.
2. Permert J, Ihse I, Jorfeldt L, et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993;159:101-7.
3. Gullo L, Ancona D, Pezzilli R, et al. Glucose tolerance and insulin secretion in pancreatic cancer. Ital J Gastroenterol 1993;25:487-9.
4. Fogar P, Pasquali C, Basso D, et al. Diabetes mellitus in pancreatic cancer follow-up. Anticancer Res 1994;14:2827-30.
5. Permert J, Adrian TE, Jacobsson P, et al. Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor? Am J Surg 1993;165:61-6; discussion 66-7.
6. Cersosimo E, Pisters PW, Pesola G, et al. Insulin secretion and action in patients with pancreatic cancer. Cancer 1991;67:486-93.
7. Permert J, Ihse I, Jorfeldt L, et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993;80:1047-50.
8. Li J, Adrian TE. A factor from pancreatic and colonic cancer cells stimulates glucose uptake and lactate production in myoblasts. Biochem Biophys Res Commun 1999;260:626-33.
9. Le Roith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001;24:588-97.
10. Andreasson K, Galuska D, Thorne A, et al. Decreased insulin-stimulated 3-0-methylglucose transport in in vitro incubated muscle strips from type II diabetic subjects. Acta Physiol Scand 1991;142:255-60.
11. Bonadonna RC, Del Prato S, Bonora E, et al. Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. Diabetes 1996;45:915-25.
12. Dohm GL, Tapscott EB, Pories WJ, et al. An in vitro human muscle preparation suitable for metabolic studies: decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects. J Clin Invest 1988;82:486-94.
13. Kelley DE, Mintun MA, Watkins SC, et al. The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 1996;97:2705-13.
14. Bjornholm M, Kawano Y, Lehtihet M, et al. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3- kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 1997;46:524-7.
15. Krook A, Roth RA, Jiang XJ, et al. Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from NIDDM subjects. Diabetes 1998;47:1281-6.
16. Krook A, Bjornholm M, Galuska D, et al. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 2000;49:284-92.
17. Liu J, Knezetic JA, Strommer L, et al. The intracellular mechanism of insulin resistance in pancreatic cancer patients. J Clin Endocrinol Metab 2000;85:1232-8.
18. Wallberg-Henriksson H, Zetan N, Henriksson J. Reversibility of decreased insulin-stimulated glucose transport capacity in diabetic muscle with in vitro incubation: insulin is not required. J Biol Chem 1987;262:7665-71.
19. Zierath JR. In vitro studies of human skeletal muscle: hormonal and metabolic regulation of glucose transport. Acta Physiol Scand Suppl 1995;626:1-96.
20. Lombardi AM, Moller D, Loizeau M, et al. Phenotype of transgenic mice overexpressing GLUT4 and hexokinase II in muscle. Faseb J 1997;11:1137-44.
21. Ren JM, Marshall BA, Gulve EA, et al. Evidence from transgenic mice that glucose transport is rate-limiting for glycogen deposition and glycolysis in skeletal muscle. J Biol Chem 1993;268:16113-5.
22. Furler SM, Jenkins AB, Storlien LH, et al. In vivo location of the rate-limiting step of hexose uptake in muscle and brain tissue of rats. Am J Physiol 1991;261:E337-47.
23. Pedersen O, Bak JF, Andersen PH, et al. Evidence against altered expression of GLUT1 or GLUT4 in skeletal muscle of patients with obesity or NIDDM. Diabetes 1990;39:865-70.
24. Miura T, Suzuki W, Ishihara E, et al. Impairment of insulin-stimulated GLUT4 translocation in skeletal muscle and adipose tissue in the Tsumura Suzuki obese diabetic mouse: a new genetic animal model of type 2 diabetes. Eur J Endocrinol 2001;145:785-90.
25. Garvey WT, Maianu L, Zhu JH, et al. Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J Clin Invest 1998;101:2377-86.
26. Kausch C, Krutzfeldt J, Witke A, et al. Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. Biochem Biophys Res Commun 2001;280:664-74.
27. Kim YB, Ciaraldi TP, Kong A, et al. Troglitazone but not Metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110? Protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 2002;51:443-8.
28. Kawa S, Nikaido T, Unno H, et al. Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas 2002;24:1-7.